• In May 2026, Nektar Therapeutics announced a US$150 million at-the-market follow-on equity offering and a leadership transition, with seasoned FLG Partners executive Linda Rubinstein replacing retiring interim CFO Sandra Gardiner.
• The appointment of Rubinstein, who has helped raise more than US$5 billion and overseen over US$1 billion in M&A value, highlights Nektar’s focus on experienced capital markets leadership as it continues to fund its pipeline.
• Next, we’ll examine how this US$150 million at-the-market equity program may influence Nektar’s investment narrative and risk profile.

Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

Nektar Therapeutics Investment Narrative Recap

To own Nektar, you really have to believe that REZPEG can turn a pre commercial, loss making biotech into a viable autoimmune franchise while the company manages its cash burn. The new US$150 million at the market program and interim CFO change look more like an extension of Nektar’s existing funding toolkit than a shift in near term clinical catalysts, but they do reinforce financing and dilution as key short term risks.

Among the latest announcements, the Q1 2026 results matter most here: revenue was US$10.86 million against a net loss of US$44.9 million. Set against repeated equity raises, this loss profile underlines why balance sheet strength and access to capital now sit alongside REZPEG’s Phase 3 progress as central parts of the story that could influence both upside potential and downside risk.

Yet even if REZPEG advances as planned, investors should be aware that ongoing dilution risk and sustained losses could still...

Nektar Therapeutics' narrative projects $46.8 million revenue and $9.1 million earnings by 2029. This assumes revenues will decline by 5.4% per year and requires an earnings increase of about $173.2 million from -$164.1 million today.

Uncover how Nektar Therapeutics' forecasts yield a $144.25 fair value, a 108% upside to its current price.

Exploring Other Perspectives

Compared with the baseline, the most bullish analysts were far more optimistic, once projecting revenue of about US$132.1 million and earnings of US$23.8 million, which shows how differently you can view the same company and why this new financing round might prompt you to revisit both optimistic and cautious scenarios.

Explore 3 other fair value estimates on Nektar Therapeutics - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Nektar Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Nektar Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nektar Therapeutics' overall financial health at a glance.

No Opportunity In Nektar Therapeutics?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.